News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,688 Results
Type
Article (9304)
Company Profile (45)
Press Release (264339)
Section
Business (74240)
Career Advice (358)
Deals (16430)
Drug Delivery (37)
Drug Development (40955)
Employer Resources (29)
FDA (7518)
Job Trends (5646)
News (140359)
Policy (13255)
Tag
2024 BioMidwest Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (1)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
Academia (716)
Accelerated approval (2)
Adcomms (10)
Allergies (40)
Alliances (18607)
ALS (30)
Alzheimer's disease (650)
Antibody-drug conjugate (ADC) (41)
Approvals (7550)
Artificial intelligence (115)
Autoimmune disease (9)
Automation (7)
Bankruptcy (152)
Best Places to Work (5192)
BIOSECURE Act (5)
Biosimilars (27)
Biotechnology (43)
Bladder cancer (46)
Brain cancer (16)
Breast cancer (106)
Cancer (1151)
Cardiovascular disease (77)
Career advice (314)
Career pathing (4)
CAR-T (92)
Cell therapy (234)
Cervical cancer (12)
Clinical research (34406)
Collaboration (356)
Compensation (97)
Complete response letters (7)
COVID-19 (878)
CRISPR (19)
C-suite (80)
Cystic fibrosis (37)
Data (1307)
Denatured (1)
Depression (18)
Diabetes (114)
Diagnostics (2665)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (54)
Drug pricing (47)
Drug shortages (17)
Duchenne muscular dystrophy (52)
Earnings (35844)
Editorial (13)
Employer branding (1)
Employer resources (24)
Events (36880)
Executive appointments (263)
FDA (8203)
Featured Employer (8)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (307)
Gene editing (49)
Generative AI (11)
Gene therapy (148)
GLP-1 (224)
Government (1466)
Grass and pollen (2)
Guidances (36)
Healthcare (7305)
Huntington's disease (4)
IgA nephropathy (14)
Immunology and inflammation (39)
Indications (19)
Infectious disease (947)
Inflammatory bowel disease (64)
Inflation Reduction Act (6)
Influenza (28)
Intellectual property (51)
Interviews (49)
IPO (8720)
IRA (17)
Job creations (743)
Job search strategy (273)
Kidney cancer (7)
Labor market (7)
Layoffs (52)
Leadership (3)
Legal (2411)
Liver cancer (38)
Lung cancer (159)
Lymphoma (80)
Machine learning (2)
Management (8)
Manufacturing (119)
MASH (36)
Medical device (5635)
Medtech (5636)
Mergers & acquisitions (8069)
Metabolic disorders (290)
Multiple sclerosis (39)
NASH (8)
Neurodegenerative disease (28)
Neuropsychiatric disorders (4)
Neuroscience (865)
NextGen: Class of 2025 (1897)
Non-profit (916)
Northern California (1339)
Now hiring (1)
Obesity (147)
Opinion (83)
Ovarian cancer (53)
Pain (40)
Pancreatic cancer (47)
Parkinson's disease (68)
Partnered (5)
Patents (123)
Patient recruitment (58)
Peanut (20)
People (18202)
Pharmaceutical (10)
Pharmacy benefit managers (6)
Phase I (10959)
Phase II (15209)
Phase III (11385)
Pipeline (737)
Podcasts (4)
Policy (41)
Postmarket research (917)
Preclinical (4035)
Press Release (52)
Prostate cancer (54)
Psychedelics (11)
Radiopharmaceuticals (136)
Rare diseases (161)
Real estate (1508)
Recruiting (9)
Regulatory (10315)
Reports (22)
Research institute (666)
Resumes & cover letters (49)
Rett syndrome (3)
RNA editing (2)
RSV (17)
Schizophrenia (28)
Series A (53)
Series B (37)
Service/supplier (3)
Sickle cell disease (23)
Southern California (1112)
Special edition (3)
Spinal muscular atrophy (34)
Sponsored (17)
Startups (889)
Stomach cancer (6)
Supply chain (22)
Tariffs (1)
The Weekly (2)
United States (11074)
Vaccines (203)
Venture capitalists (6)
Webinars (2)
Weight loss (83)
Women's health (8)
Worklife (4)
Date
Today (48)
Last 7 days (418)
Last 30 days (1533)
Last 365 days (18236)
2025 (4457)
2024 (18932)
2023 (21244)
2022 (26943)
2021 (29001)
2020 (26412)
2019 (17812)
2018 (13211)
2017 (13846)
2016 (11843)
2015 (14237)
2014 (9955)
2013 (7545)
2012 (7760)
2011 (8467)
2010 (7724)
Location
Africa (243)
Alabama (16)
Alaska (4)
Arizona (56)
Arkansas (4)
Asia (20530)
Australia (5321)
California (2968)
Canada (1127)
China (260)
Colorado (123)
Connecticut (167)
Delaware (66)
Europe (37824)
Florida (414)
Georgia (93)
Idaho (12)
Illinois (216)
India (19)
Indiana (142)
Iowa (3)
Japan (99)
Kansas (17)
Kentucky (5)
Louisiana (4)
Maine (41)
Maryland (381)
Massachusetts (2136)
Michigan (55)
Minnesota (119)
Missouri (41)
Montana (13)
Nebraska (8)
Nevada (38)
New Hampshire (41)
New Jersey (1073)
New Mexico (12)
New York (901)
North Carolina (442)
North Dakota (3)
Northern California (1339)
Ohio (64)
Oklahoma (2)
Oregon (8)
Pennsylvania (679)
Puerto Rico (4)
Rhode Island (8)
South America (363)
South Carolina (8)
Southern California (1112)
Tennessee (46)
Texas (436)
Utah (68)
Virginia (74)
Washington D.C. (21)
Washington State (349)
West Virginia (2)
Wisconsin (12)
273,688 Results for "iaso biotherapeutics usa limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Comprehensively Covering Multiple Myeloma: IASO Bio’s GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
IASO Biotechnology (“IASO Bio”) today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM).
June 28, 2024
·
5 min read
Press Releases
Shimadzu Medical Systems USA announces leadership change
April 1, 2025
·
1 min read
Biotech Bay
IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024
IASO biotechnology presented the clinical data and single-cell analysis of the fully human anti-BCMA CAR T cell therapy for the treatment of central nervous system autoimmunity in an oral presentation at the 2024 European Academy of Neurology Annual Meeting.
July 1, 2024
·
5 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Policy
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).
May 20, 2024
·
3 min read
Biotech Bay
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024
IASO biotechnology presented clinical data on the use of Equecabtagene Autoleucel, the world’s first approved fully human CAR-T product, for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma in an oral presentation at the 2024 European Hematology Association Annual Congress.
June 15, 2024
·
5 min read
Press Releases
Lisata Therapeutics to Present at the Investival Showcase USA
March 6, 2025
·
1 min read
Biotech Bay
IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
IASO Biotherapeutics announced a new set of collaborations with Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, for the development and commercialization of novel ex vivo and in vivo cell and gene therapies.
January 3, 2024
·
5 min read
Press Releases
Final Call for Biocodex Microbiota Foundation $50,000 2025 USA Microbiome Research Grant
April 2, 2025
·
2 min read
Press Releases
Telix Completes Acquisition of RLS (USA) Inc.
January 27, 2025
·
8 min read
1 of 27,369
Next